Ocugen, Inc.
(NASDAQ : OCGN)

( )
OCGN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
1.07%200.801.3%$462.93m
BIIBBiogen Inc.
0.09%223.211.3%$371.70m
GILDGilead Sciences, Inc.
-0.09%63.930.9%$362.66m
CELGCelgene Corporation
0.76%100.571.3%$359.89m
ILMNIllumina, Inc.
1.48%302.583.5%$282.38m
REGNRegeneron Pharmaceuticals, Inc.
0.81%300.772.6%$210.74m
EXASExact Sciences Corporation
2.19%92.5024.1%$193.04m
VRTXVertex Pharmaceuticals Incorporated
1.29%172.411.9%$181.51m
ALXNAlexion Pharmaceuticals, Inc.
0.92%99.252.0%$176.54m
AAgilent Technologies, Inc.
1.77%75.311.6%$166.98m
SRPTSarepta Therapeutics, Inc.
0.39%83.4814.6%$138.14m
ALDRAlder Biopharmaceuticals, Inc.
-0.05%18.8710.2%$125.33m
BMRNBioMarin Pharmaceutical Inc.
1.29%67.364.3%$96.05m
ACADACADIA Pharmaceuticals Inc.
0.10%40.5213.4%$95.97m
INCYIncyte Corporation
0.46%76.122.5%$87.99m

Company Profile

Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline of therapies includes OCU400, OCU410, OCU200, OCU100, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.